Onderzoeksbeurs Emmanuel Van de Schueren aan Suzanne Vanhauwaert: BRIP1 en BIRC5 as novel therapeutic targets in neuroblastoma
Validatie van ferroptose-sensitizerende combinatie therapieën in patiënt-afkomstige neuroblastoma modellen.
Validatie van ferroptose-sensitizerende combinatie therapieën in patiënt-afkomstige neuroblastoma modellen
Bepalen van (+)-jq1-drug-chromatine-interacties die aan de basis liggen van ferroptosis-sensitisatie in neuroblastoma.
Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study
Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
A novel standard for systematic reporting of neuroblastoma surgery : the International Neuroblastoma Surgical Report Form (INSRF), a joint initiative by the Pediatric Oncological Cooperative Groups SIOPEN, COG and GPOH
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation